Latest News

Study using DFMO shows positive results for children with high risk neuroblastoma

A paper published September 27 in Scientific Reports shows the positive results of a phase II clinical trial using the oral medication DFMO to prevent relapse in children with High Risk Neuroblastoma.

Source link

Related posts

Researchers describe new ALS biomarkers, potential new drug targets


Medical marijuana bill clears Senate


Intravenous drugs can often rapidly restore normal heart rhythm without sedation, shocks


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy